Janssen develops mobile clinical trials platform to reduce drug development costs, improve adherence

Janssen’s iSTEP platform is part of an ongoing effort by pharma companies to reduce the cost of drug development and address the complexities of having multiple sites for these trials in different countries.

Janssen iSTEP is designed to improve medication adherence for clinical trials and make them cheaper to run.

In what could be a milestone development for clinical trial design by big pharma companies, Janssen, which is the pharma arm of Johnson and Johnson, has unveiled a set of tools to automate investigational products and data management in clinical trials, according to a news release. The goal is to improve medication adherence across multiple trial sites in different countries.

The Integrated Smart Trial and Engagement Platform, or iSTEP has a few components. Connected medication blister packs note when each pill has been taken. Electronic drug labels make it easier to convey medication information in the participant’s language. Another component, eCommunication, makes it easier to customize information to individual trial participants. Videos and patient notifications can be conveyed via smartphone.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

Close up of connected medication blister pack for iSTEP from Janssen.

Janssen’s iSTEP is the product of a five-year quest by the drug developer to produce a platform that supports medication management and patient engagement. A pilot to evaluate iSTEP’s remote monitoring capabilities included  24 healthy volunteers varying in age from 18 to more than 65 years old with a mix of Dutch, French, and English speakers.

It produced a compliance rate of 92 percent with 84 percent saying iSTEP was easy to use.

Dr. Andreas Koester, Vice President of Innovation with Janssen Research and Development Operations, said in response to emailed questions that Janssen developed iSTEP in collaboration with Tata Consulting Services. Tata is also responsible for licensing iSTEP to biotech and pharma companies and other businesses interested in using it.

Koester said iSTEP has a web portal and an app. As the platform evolves, he said more interaction modes will be added.

“A key feature of the platform is its ability to easily interact with existing and future systems and technologies, such as electronic patient-reported outcomes, eConsent, and sensor data,” he said “To our knowledge, there are no other platforms available with similar functionality to iSTEP, which was a major driver in our decision to develop this innovative solution in coop with TCS.”